Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure*

Luchetti, Marco; Ferrero, Federica; Gallini, Carla; Natale, Alfonso; Pigna, A; Tortorolo, Luca; Marraro, Giuseppe A.

doi:10.1097/00130478-200207000-00011

Cited by 92 publications

(61 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Luchetti et al [134] reported that 10 infants with RSVbronchiolitis treated with tracheally-instilled porcine-derived surfactant (Curosurf®, 50 mg/kg body weight) had improved gas exchange and a reduced time on mechanical ventilation and in the pediatric intensive care unit compared to an equal number of control infants not treated with exogenous surfactant. A subsequent multicenter controlled trial in 40 patients also found that surfactant therapy with Curosurf® improved gas exchange and respiratory mechanics, and shortened the duration of mechanical ventilation and hospitalization, in infants with acute respiratory failure from RSV bronchiolitis [135]. Also, Tibby et al [139] have reported that 9 infants with severe RSV bronchiolitis who received two doses of Survanta® (100 mg/kg) had a more rapid improvement in oxygenation and ventilation indices in the first 60 hours compared to 10 control infants receiving air-placebo.…”

Section: Current Studies On Surfactant Replacement Therapy In Patmentioning

confidence: 96%

“…A significant number of clinical studies have reported benefits following the instillation of exogenous surfactants to term infants, children, or adults with ALI/ARDS or related acute respiratory failure [25,[120][121][122][123][124][125][126][127][128][129][130][131][132][133][134][135] (Table 4). However, many of these are small case series or pilot studies, and found only improvements in acute lung function (oxygenation).…”

Section: Current Studies On Surfactant Replacement Therapy In Patmentioning

confidence: 99%

“…A subsequent multicenter controlled trial in 328 term infants also reported significant improvements in respiratory status and the need for ECMO following surfactant treatment [131]. Surfactant therapy has also been found to be beneficial to lung function or respiratory outcome in several studies in infants with viral respiratory (RSV) infection [134,135,139]. Luchetti et al [134] reported that 10 infants with RSVbronchiolitis treated with tracheally-instilled porcine-derived surfactant (Curosurf®, 50 mg/kg body weight) had improved gas exchange and a reduced time on mechanical ventilation and in the pediatric intensive care unit compared to an equal number of control infants not treated with exogenous surfactant.…”

Section: Current Studies On Surfactant Replacement Therapy In Patmentioning

confidence: 99%

See 2 more Smart Citations

Surfactant for Pediatric Acute Lung Injury

Willson¹,

Chess²,

Notter³

2008

Pediatric Clinics of North America

View full text Add to dashboard Cite

SynopsisThis article reviews exogenous surfactant therapy and its use in mitigating acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) in infants, children, and adults. Biophysical and animal research documenting surfactant dysfunction in ALI/ARDS is described, and the scientific rationale for treatment with exogenous surfactant is discussed. Major emphasis is on reviewing clinical studies of surfactant therapy in pediatric and adult patients with ALI/ARDS. Particular advantages from surfactant therapy in direct pulmonary forms of these syndromes are described. Also discussed are additional factors affecting the efficacy of exogenous surfactants in ALI/ARDS, including the multifaceted pathology of inflammatory lung injury, the effectiveness of surfactant delivery in injured lungs, and composition-based activity differences among clinical exogenous surfactant preparations.

show abstract

Section: Current Studies On Surfactant Replacement Therapy In Patmentioning

confidence: 96%

Section: Current Studies On Surfactant Replacement Therapy In Patmentioning

confidence: 99%

Section: Current Studies On Surfactant Replacement Therapy In Patmentioning

confidence: 99%

See 1 more Smart Citation

Surfactant for Pediatric Acute Lung Injury

Willson¹,

Chess²,

Notter³

2008

Pediatric Clinics of North America

View full text Add to dashboard Cite

show abstract

“…Recently, poractant alfa treatment in infants with respiratory syncytial virus pneumonia has been shown to improve gas exchange and lung compliance. 44 …”

Section: Surfactant Therapy and Nasal Continuous Positive Airway Presmentioning

confidence: 99%

Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS

Ramanathan

2006

J Perinatol

View full text Add to dashboard Cite

Many different surfactant preparations derived from animal sources, as well as synthetic surfactants, are available for the treatment of preterm infants with respiratory distress syndrome (RDS). Natural, modified surfactants containing surfactant-associated proteins appear to be more effective than non-protein-containing synthetic surfactants. Comparative trials with poractant alfa at a higher initial dose of 200 mg/kg appear to be associated with rapid weaning of FiO 2 , less need for additional doses, and decreased mortality in infants <32 weeks gestation when compared with beractant. Early rescue (<30 min of age) surfactant therapy is an effective method to minimize over treatment of some preterm infants who may not develop RDS. Surfactant therapy followed by rapid extubation to nasal ventilation appears to be more beneficial than continued mechanical ventilation. In near-term or term newborns with acute RDS, surfactant therapy has been shown to be 70% effective in improving respiratory failure.

show abstract

“…Luchetti et al (10,12) used porcine surfactant and no placebo in both studies. Tibby et al (11) used bovine surfactant and an air placebo.…”

Section: Surfactantmentioning

confidence: 99%

Efficacy of interventions for bronchiolitis in critically ill infants: A systematic review and meta-analysis*

Davison

Ventre²,

Luchetti³

et al. 2004

Pediatric Critical Care Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure*

Cited by 92 publications

References 29 publications

Surfactant for Pediatric Acute Lung Injury

Surfactant for Pediatric Acute Lung Injury

Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS

Efficacy of interventions for bronchiolitis in critically ill infants: A systematic review and meta-analysis*

Contact Info

Product

Resources

About